The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

被引:188
作者
Mega, MS
Masterman, DM
O'Connor, SM
Barclay, TR
Cummings, JL
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Alzheimers Dis Res Ctr, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA
关键词
D O I
10.1001/archneur.56.11.1388
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Behavioral abnormalities are common in Alzheimer disease (AD); cholinergic treatment reduces the behavioral disturbances of some patients with AD. Characterizing the pretreatment profile of patients who are likely to respond to cholinergic therapy will aid the efficient use of clinical resources. Objective: To determine the baseline behavioral profile for 86 patients with AD treated with the cholinesterase inhibitor donepezil hydrochloride. Methods: Open-label retrospective study of treatment-related behavioral assessments. Based on previous double-blind placebo-controlled experience using the Neuropsychiatric Inventory (NPI), patients were divided into responder (greater than or equal to 4-point total NPI score decrease, indicating improvement), unchanged (+/-3-point total NPI score change),or nonresponder (greater than or equal to 4-point total NPI score increaser indicating worsening) groups. The Mini-Mental State Examination assessed cognitive response. Results: Behavioral improvement was seen in 35 patients (41%), worsening in 24 (28%), and no change in 27 (31%). Comparison of profiles in behavioral responders vs nonresponders revealed significantly worse delusions (P = .04), agitation (P = .04): depression (P = .006) anxiety (P = .02), apathy (P = .003); disinhibition (P = .02), and irritability (P < .001) at baseline in responders. Five behaviors changed significantly from baseline, improving for the responders and worsening for the nonresponders: delusions (P = .003 for nonresponders, P = .004 fbr responders), agitation (P = .01), anxiety (P = .006 for nonresponders, P = .004 for responders), disinhibition (P = .02 for nonresponders, P = .05 for responders), and irritability (P = .003 for nonresponders, P = .001 for responders). The behavioral changes were dose dependent. Cognition did not change significantly with donepezil treatment within any group. Conclusions: Donepezil has psychotropic properties, and pretreatment behaviors help predict patients' responses to treatment.
引用
收藏
页码:1388 / 1393
页数:6
相关论文
共 21 条
[1]   METABOLIC EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE IN HUMAN BRAIN - MEASURED BY POSITRON EMISSION TOMOGRAPHY [J].
BLIN, J ;
PIERCEY, MF ;
GIUFFRA, ME ;
MOURADIAN, MM ;
CHASE, TN .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 123 (1-2) :44-51
[2]   Cerebral blood flow correlates of apathy in Alzheimer disease [J].
Craig, AH ;
Cummings, JL ;
Fairbanks, L ;
Itti, L ;
Miller, BL ;
Li, J ;
Mena, I .
ARCHIVES OF NEUROLOGY, 1996, 53 (11) :1116-1120
[3]   REVERSIBLE DEMENTIA - ILLUSTRATIVE CASES, DEFINITION, AND REVIEW [J].
CUMMINGS, J ;
BENSON, DF ;
LOVERME, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (23) :2434-2439
[4]   PHYSOSTIGMINE AMELIORATES THE DELUSIONS OF ALZHEIMERS-DISEASE [J].
CUMMINGS, JL ;
GORMAN, DG ;
SHAPIRA, J .
BIOLOGICAL PSYCHIATRY, 1993, 33 (07) :536-541
[5]  
Cummings JL, 1998, NEUROLOGY, V50, pA251
[6]   THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].
CUMMINGS, JL ;
MEGA, M ;
GRAY, K ;
ROSENBERGTHOMPSON, S ;
CARUSI, DA ;
GORNBEIN, J .
NEUROLOGY, 1994, 44 (12) :2308-2314
[7]  
CUMMINGS JL, 1992, CLIN APPROACH
[8]   STATISTICAL-DATA ANALYSIS IN THE COMPUTER-AGE [J].
EFRON, B ;
TIBSHIRANI, R .
SCIENCE, 1991, 253 (5018) :390-395
[9]   A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE [J].
FARLOW, M ;
GRACON, SI ;
HERSHEY, LA ;
LEWIS, KW ;
SADOWSKY, CH ;
DOLANURENO, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18) :2523-2529
[10]  
FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P89